ArticleCancer management and research2025
High PD-L2 Expression Is Associated with Better Disease-Free Survival in Patients with Intrahepatic Cholangiocarcinoma.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: PD-L2 is expressed in various cancer tissues. Currently, the value of PD-L2 expression in intrahepatic cholangiocarcinoma (ICC) tissues remains unclear. This study investigated the prognostic and clinical significance of PD-L2 expression in ICC. Methods: This research employs The Cancer Genome Atlas (TCGA) database to examine the expression profiles of PD-L2 in ICC and to evaluate its prognostic significance. Immunohistochemistry detected PD-L2 expression in 66 postoperative ICC tissues and paired adjacent tissues. Correlations between PD-L2 expression and clinicopathological data were analyzed. Kaplan-Meier survival analysis and Cox proportional hazards regression model were used to evaluate the prognostic value of PD-L2. Results: Bioinformatics analysis shows that high expression of PD-L2 dominates in early ICC patients and is closely associated with tumor recurrence. High PD-L2 expression is associated with longer progression free survival (PFS) ( Conclusion: PD-L2 expression is predominantly high in patients with early-stage ICC. PD-L2 expression serves as an independent predictor of DFS in patients with ICC following hepatectomy. ICC patients with elevated PD-L2 expression levels exhibit delayed relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.